The Latest Breaking News from Eli Lilly

U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis.

Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 4.0% since last its last report. The company recently reported that it has 6.19 million shares sold short, which is 0.78% of all regular shares that are available for trading.